MEDP Medpace Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MEDP

Price (delayed)

$662.495

Market cap

$18.53B

P/E Ratio

36.12

Dividend/share

N/A

EPS

$18.34

Enterprise value

$17.97B

?
Relative Growth: Rel. Growth: 96
Relative Strength: Rel. Strength: 81
Relative Valuation: Rel. Valuation: 28
Relative Profitability: Rel. Profitability: 50

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate ...

Highlights
Medpace Holdings's equity has soared by 99% YoY and by 35% from the previous quarter
Medpace Holdings's quick ratio has surged by 51% YoY and by 17% QoQ
The debt is up by 23% year-on-year and by 22% since the previous quarter
The P/E is 19% higher than the 5-year quarterly average of 30.0 and 10% higher than the last 4 quarters average of 32.5
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.medpace.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of MEDP

MEDP stock price

How has the Medpace Holdings stock price performed over time
Intraday
0.87%
1 week
-2.22%
1 month
6.77%
1 year
10.64%
YTD
17.96%
QTD
6.14%

Financial performance

How have Medpace Holdings's revenue and profit performed over time
Revenue
$2.84B
Gross profit
$827.16M
Operating income
$607.14M
Net income
$517.83M
Gross margin
29.1%
Net margin
18.2%
The net income has increased by 20% YoY and by 5% from the previous quarter
The operating income has increased by 20% year-on-year and by 4.1% since the previous quarter
MEDP's revenue is up by 20% year-on-year and by 2% since the previous quarter
MEDP's gross profit is up by 13% year-on-year and by 3.4% since the previous quarter

Price vs fundamentals

How does MEDP's price correlate with its fundamentals

Growth

What is Medpace Holdings's growth rate over time

Valuation

What is Medpace Holdings stock price valuation
MEDP P/E details
P/E
36.12
P/B
31.61
P/S
6.52
EV/EBIT
29.26
EV/EBITDA
27.01
EV/Sales
6.33
The EPS is up by 25% YoY and by 6% QoQ
The P/E is 19% higher than the 5-year quarterly average of 30.0 and 10% higher than the last 4 quarters average of 32.5
Medpace Holdings's equity has soared by 99% YoY and by 35% from the previous quarter
MEDP's price to book (P/B) is 44% higher than its 5-year quarterly average of 21.7 and 2.8% higher than its last 4 quarters average of 30.5
MEDP's price to sales (P/S) is 29% more than its 5-year quarterly average of 5.0 and 11% more than its last 4 quarters average of 5.8
MEDP's revenue is up by 20% year-on-year and by 2% since the previous quarter

Efficiency

How efficient is Medpace Holdings business performance
The company's return on equity fell by 9% QoQ but it rose by 9% YoY
Medpace Holdings's return on assets has increased by 3.4% YoY
The ROS is up by 2.9% YoY and by 2.4% QoQ

Dividends

What is MEDP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MEDP.

Financial health

How did Medpace Holdings financials performed over time
The company's total assets is 34% higher than its total liabilities
Medpace Holdings's quick ratio has surged by 51% YoY and by 17% QoQ
Medpace Holdings's current ratio has increased by 46% YoY and by 14% QoQ
The debt is 75% smaller than the equity
Medpace Holdings's equity has soared by 99% YoY and by 35% from the previous quarter
MEDP's debt to equity is down by 39% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.